<DOC>
	<DOCNO>NCT00057265</DOCNO>
	<brief_summary>This study conduct compare safety effectiveness investigational medication , LdT ( Telbivudine ) Lamivudine , drug currently approve US , European Asian Health Authorities treatment hepatitis B infection . The result patient take LdT compare result patient take Lamivudine .</brief_summary>
	<brief_title>A Randomized , Double Blind Trial LdT ( Telbivudine ) Versus Lamivudine Adults With Compensated Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Chronic Hepatitis B , document Clinical history compatible chronic HBV Other protocoldefined inclusion criterion may apply . Patient pregnant breastfeeding Patient co infect hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) , HIV1 HIV2 . Patient previously receive lamivudine investigational antiHBV nucleoside nucleotide analog time Patient receive interferon immunomodulatory treatment HBV infection 12 month screen study Other protocol define exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>